• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    2/14/22 4:40:59 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CADL alert in real time by email
    SC 13G 1 tm226606d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G
    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) 

    AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

    (Amendment No. )*

     

    Candel Therapeutics Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

     

    137404109

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨       Rule 13d-1(b)

    ¨       Rule 13d-1(c)

    x      Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP NO. 137404109 13 G  

     

    1 NAMES OF REPORTING PERSONS.
    Northpond Ventures, LP
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ¨    (b) x (1)

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    0 shares
      6 SHARED VOTING POWER
    1,685,215 shares (2)
      7 SOLE DISPOSITIVE POWER
    0 shares
      8 SHARED DISPOSITIVE POWER
    1,685,215 shares (2)
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,685,215 shares (2)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*                                                                        ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    5.9% of Common Stock (3)
    12

    TYPE OF REPORTING PERSON*

    PN

                   

     

    (1)This statement on Schedule 13G is filed by Northpond Ventures, LP (“Northpond Fund”), Northpond Ventures GP, LLC (“Northpond GP LLC”), Northpond Ventures II, LP (“Northpond Fund II”), Northpond Ventures II GP, LLC (“Northpond GP II LLC”) and Michael P. Rubin (“Rubin” and, together with Northpond Fund, Northpond GP LLC, Northpond Fund II and Northpond GP II LLC, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)The shares are held by Northpond Fund. Northpond GP LLC is the general partner of Northpond Fund. Rubin is the managing member of Northpond GP LLC. As such, Northpond GP LLC and Rubin have shared dispositive and voting power over the shares held by Northpond Fund and may be deemed to have indirect beneficial ownership of the shares held by Northpond Fund. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2021.

    (3)The Common Stock beneficial ownership percentage is based on a total of 28,689,842 shares of Common Stock outstanding as of November 11, 2021, as reported on the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the SEC on November 12, 2021.

     

     

     

     

    CUSIP NO. 137404109 13 G  

     

    1 NAMES OF REPORTING PERSONS.
    Northpond Ventures II GP, LLC
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ¨    (b) x (1)

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    0 shares
      6 SHARED VOTING POWER
    1,685,215 shares (2)
      7 SOLE DISPOSITIVE POWER
    0 shares
      8 SHARED DISPOSITIVE POWER
    1,685,215 shares (2)
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,685,215 shares (2)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*                                                                        ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    5.9% of Common Stock (3)
    12

    TYPE OF REPORTING PERSON*

    OO

                   

     

    (1)This statement on Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)The shares are held by Northpond Fund. Northpond GP LLC is the general partner of Northpond Fund. Rubin is the managing member of Northpond GP LLC. As such, Northpond GP LLC and Rubin have shared dispositive and voting power over the shares held by Northpond Fund and may be deemed to have indirect beneficial ownership of the shares held by Northpond Fund. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2021.

    (3)The Common Stock beneficial ownership percentage is based on a total of 28,689,842 shares of Common Stock outstanding as of November 11, 2021, as reported on the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the SEC on November 12, 2021.

     

     

     

     

    CUSIP NO. 137404109 13 G  

     

    1 NAMES OF REPORTING PERSONS.
    Northpond Ventures II, LP
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ¨    (b) x (1)

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    0 shares
      6 SHARED VOTING POWER
    250,000 shares (2)
      7 SOLE DISPOSITIVE POWER
    0 shares
      8 SHARED DISPOSITIVE POWER
    250,000 shares (2)
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    250,000 shares (2)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*                                                                        ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    0.9% of Common Stock (3)
    12

    TYPE OF REPORTING PERSON*

    PN

                   

     

    (1)This statement on Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)The shares are held by Northpond Fund II. Northpond GP II LLC is the general partner of Northpond Fund II. Rubin is the managing member of Northpond GP II LLC. As such, Northpond GP II LLC and Rubin have shared dispositive and voting power over the shares held by Northpond Fund II and may be deemed to have indirect beneficial ownership of the shares held by Northpond Fund II. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2021.

    (3)The Common Stock beneficial ownership percentage is based on a total of 28,689,842 shares of Common Stock outstanding as of November 11, 2021, as reported on the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the SEC on November 12, 2021.

     

     

     

     

    CUSIP NO. 137404109 13 G  

     

    1 NAMES OF REPORTING PERSONS.
    Northpond Ventures II GP , LLC
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ¨    (b) x (1)

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    0 shares
      6 SHARED VOTING POWER
    250,000 shares (2)
      7 SOLE DISPOSITIVE POWER
    0 shares
      8 SHARED DISPOSITIVE POWER
    250,000 shares (2)
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    250,000 shares (2)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*                                                                        ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    0.9% of Common Stock (3)
    12

    TYPE OF REPORTING PERSON*

    OO

                   

     

    (1)This statement on Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)The shares are held by Northpond Fund II. Northpond GP II LLC is the general partner of Northpond Fund II. Rubin is the managing member of Northpond GP II LLC. As such, Northpond GP II LLC and Rubin have shared dispositive and voting power over the shares held by Northpond Fund II and may be deemed to have indirect beneficial ownership of the shares held by Northpond Fund II. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2021.

    (3)The Common Stock beneficial ownership percentage is based on a total of 28,689,842 shares of Common Stock outstanding as of November 11, 2021, as reported on the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the SEC on November 12, 2021.

     

     

     

     

    CUSIP NO. 137404109 13 G  

     

    1 NAMES OF REPORTING PERSONS.
    Michael P. Rubin
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ¨    (b) x (1)

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    0 shares
      6 SHARED VOTING POWER
    1,935,215 shares (2)
      7 SOLE DISPOSITIVE POWER
    0 shares
      8 SHARED DISPOSITIVE POWER
    1,935,215 shares (2)
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,935,215 shares (2)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*                                                                        ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    6.7% of Common Stock (3)
    12

    TYPE OF REPORTING PERSON*

    IN

                   

     

    (1)This statement on Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)The shares are held by Northpond Fund and Northpond Fund II. Northpond GP LLC is the general partner of Northpond Fund and Northpond GP II LLC is the general partner of Northpond Fund II. Rubin is the managing member of Northond GP LLC and Northpond GP II LLC. As such, Northpond GP LLC, Northpond GP II LLC and Rubin have shared dispositive and voting power over the shares held by Northpond Fund and Northpond Fund II and may be deemed to have indirect beneficial ownership of the shares held by Northpond Fund and Northpond Fund II. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2021.

    (3)The Common Stock beneficial ownership percentage is based on a total of 28,689,842 shares of Common Stock outstanding as of November 11, 2021, as reported on the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the SEC on November 12, 2021.

     

     

     

     

    Introductory Note: This Statement on Schedule 13G (this “Statement”) is filed on behalf of the Reporting Persons, in respect of shares of Common Stock, par value $0.01 per share (“Common Stock”), of Candel Therapeutics Inc. (the “Issuer”).

     

    Item 1

     

    (a) Name of Issuer: Candel Therapeutics Inc.
         
    Address of Issuer’s Principal Executive Offices: 117 Kendrick St, Suite 450
        Needham, MA 02494
       

     

    Item 2

     

    (a)Name of Person(s) Filing:

     

    Northpond Ventures, LP (“Northpond Fund”)

    Northpond Ventures GP, LLC (“Northpond GP LLC”)

    Northpond Ventures II, LP (“Northpond Fund II”)

    Northpond Ventures II GP, LLC (“Northpond GP II LLC”)

    Michael P. Rubin (“Rubin”)

     

    (b)Address of Principal Business Office:

     

    7500 Old Georgetown Road, Suite 850

    Bethesda, MD 20814

     

    (b)Citizenship:

     

    All entities were organized in Delaware.

    Rubin is a United States citizen.

     

    (d)Title of Class of Securities:
        
     Common Stock, par value $0.01 per share.  

     

    (e)CUSIP Number:
        
     137404109  

     

      Item 3Not applicable.

     

     

     

     

    Item 4Ownership.

     

    Reporting Persons 

    Common

    Stock Held

    Directly

      

    Shared

    Voting

    Power (1)

      

    Shared

    Dispositive

    Power (2)

      

    Beneficial

    Ownership

    (1)

      

    Percentage

    of

    Common

    Stock (1) 

    (2)(3)

     
    Northpond Fund   1,685,215    1,685,215    1,685,215    1,685,215    5.9%
    Northpond GP LLC   0    1,685,215    1,685,215    1,685,215    5.9%
    Northpond Fund II   250,000    250,000    250,000    250,000    0.9%
    Northpond GP II LLC   0    250,000    250,000    250,000    0.9%
    Rubin   0    1,935,215    1,935,215    1,935,215    6.7%

     

    (1) This statement on Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)The shares are held by Northpond Fund and Northpond Fund II. Northpond GP LLC is the general partner of Northpond Fund and Northpond GP II LLC is the general partner of Northpond Fund II. Rubin is the managing member of Northond GP LLC and Northpond GP II LLC. As such, Northpond GP LLC, Northpond GP II LLC and Rubin have shared dispositive and voting power over the shares held by Northpond Fund and Northpond Fund II and may be deemed to have indirect beneficial ownership of the shares held by Northpond Fund and Northpond Fund II. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2021.

    (3)The Common Stock beneficial ownership percentage is based on a total of 28,689,842 shares of Common Stock outstanding as of November 11, 2021, as reported on the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the SEC on November 12, 2021.

     

    Item 5Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6Ownership of More Than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10Certification.

     

    Not applicable.

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2022

     

    NORTHPOND VENTURES, LP  
       
    By: Northpond Ventures GP, LLC  
    Its: General Partner  
       
    By: /s/ Patrick Smerkers  
    Name: Patrick Smerkers  
    Title: Chief Financial Officer  
         
       
    NORTHPOND VENTURES GP, LLC  
         
    By: /s/ Patrick Smerkers  
    Name: Patrick Smerkers  
    Title: Chief Financial Officer  
         
         
    NORTHPOND VENTURES II, LP  
       
    By: Northpond Ventures II GP, LLC  
    Its: General Partner  
       
    By: /s/ Patrick Smerkers  
    Name: Patrick Smerkers  
    Title: Chief Financial Officer  
         
       
    NORTHPOND VENTURES II GP, LLC  
         
    By: /s/ Patrick Smerkers  
    Name: Patrick Smerkers  
    Title: Chief Financial Officer  
         
         
    /s/ Michael P. Rubin  
    Michael P. Rubin  

     

     

     

    Get the next $CADL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CADL

    DatePrice TargetRatingAnalyst
    2/20/2025$25.00Buy
    Citigroup
    2/19/2025$20.00Buy
    Canaccord Genuity
    2/7/2025$15.00Buy
    BofA Securities
    12/2/2022$11.00Buy
    H.C. Wainwright
    11/19/2021$18.00Outperform
    BMO Capital
    8/23/2021$9.00Buy
    UBS
    8/23/2021$22.00Buy
    Jefferies
    8/23/2021$15.00Outperform
    Credit Suisse
    More analyst ratings

    $CADL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Benz Edward J. Jr

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      6/18/25 8:38:15 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Gaeta Renee

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      6/18/25 8:37:10 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Loggia Nicoletta

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      6/18/25 8:36:23 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

      NEEDHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Maha Radhakrishnan, M.D., to the Company's Board of Directors (Board) effective June 4, 2025. "We are delighted to welcome Maha as a new member of Candel's Board," said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. "Her extensive industry experience will be extremely valuable as Candel advances its late-stage oncology programs toward potential approval and commercial de

      6/6/25 8:05:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

      NEEDHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CAN-2409 (aglatimagene besadenovec), the Company's biological immunotherapy lead candidate, for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease. CAN-2409 was also previously granted FDA Fast Track designation for the same indication. The FDA's RMA

      5/28/25 8:05:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

      NEEDHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Candel management will host a webcast and conference call on Tuesday, June 3, 2025, at 1:00PM ET. The call will discuss the Company's positive phase 3 clinical results for CAN-2409 in localized, intermediate-to-high risk prostate cancer, which demonstrated a statistically significant 30% reduction in disease recurrence compared with placebo when combined with standard-of-care radiation therapy. The discussion will follow Dr.

      5/27/25 8:05:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    SEC Filings

    See more
    • Candel Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Candel Therapeutics, Inc. (0001841387) (Filer)

      6/18/25 8:30:50 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Candel Therapeutics, Inc. (0001841387) (Filer)

      6/6/25 8:11:04 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Candel Therapeutics, Inc. (0001841387) (Filer)

      5/28/25 8:10:40 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Manning Paul B bought $7,500,000 worth of shares (1,250,000 units at $6.00) (SEC Form 4)

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      12/18/24 4:11:47 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Candel Therapeutics with a new price target

      Citigroup initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $25.00

      2/20/25 6:59:49 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Canaccord Genuity initiated coverage on Candel Therapeutics with a new price target

      Canaccord Genuity initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $20.00

      2/19/25 7:01:43 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BofA Securities initiated coverage on Candel Therapeutics with a new price target

      BofA Securities initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $15.00

      2/7/25 8:23:12 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    Financials

    Live finance-specific insights

    See more
    • Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

      NEEDHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Candel management will host a webcast and conference call on Tuesday, June 3, 2025, at 1:00PM ET. The call will discuss the Company's positive phase 3 clinical results for CAN-2409 in localized, intermediate-to-high risk prostate cancer, which demonstrated a statistically significant 30% reduction in disease recurrence compared with placebo when combined with standard-of-care radiation therapy. The discussion will follow Dr.

      5/27/25 8:05:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

      Positive topline data for CAN-2409 viral immunotherapy achieved primary endpoint by demonstrating statistically significant and clinically meaningful benefit when combined with radiation therapy for intermediate-to-high risk, localized prostate cancerThe safety profile of CAN-2409 was generally consistent with previous studies, with no new safety signals identifiedThe phase 3 clinical trial was conducted under a Special Protocol Assessment (SPA) with the FDA NEEDHAM, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients

      12/11/24 7:00:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights

      Expects to announce clinical trial data from multiple oncology programs in the second half of 2023Extends cash runway into second quarter of 2024 NEEDHAM, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update. "Our 2022 achievements reaffirm our belief that using our viral immunotherapies to mobilize the patient's immune system to fight cancer represents a promising a

      3/30/23 8:00:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    Leadership Updates

    Live Leadership Updates

    See more
    • Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

      NEEDHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Maha Radhakrishnan, M.D., to the Company's Board of Directors (Board) effective June 4, 2025. "We are delighted to welcome Maha as a new member of Candel's Board," said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. "Her extensive industry experience will be extremely valuable as Candel advances its late-stage oncology programs toward potential approval and commercial de

      6/6/25 8:05:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board

      NEEDHAM, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Elizabeth M. Jaffee, M.D., to the Company's Research Advisory Board (RAB). Dr. Jaffee, an internationally recognized expert in cancer immunology and pancreatic cancer, brings her extensive expertise to the RAB, which is important in light of the Company's focus on borderline resectable pancreatic cancer. Dr. Jaffee currently serves as the Dana and Albert "Cubby" Broccoli Professor of Oncology, Deputy Dire

      3/18/25 8:00:46 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

      MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings bro

      9/4/24 8:00:00 AM ET
      $CADL
      $EBS
      $MIST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CADL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Candel Therapeutics Inc.

      SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

      12/17/24 12:30:40 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Candel Therapeutics Inc. (Amendment)

      SC 13G/A - Candel Therapeutics, Inc. (0001841387) (Subject)

      2/9/23 9:59:40 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Candel Therapeutics Inc.

      SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

      2/14/22 4:40:59 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care